Litcius/Paper detail

Long-term efficacy of house dust mite sublingual immunotherapy on clinical and pulmonary function in patients with asthma and allergic rhinitis

Makoto Hoshino, Kenta Akitsu, Junichi Ohtawa, Kengo Kubota

2024Journal of Allergy and Clinical Immunology Global11 citationsDOIOpen Access PDF

Abstract

Background: A previous study reported that house dust mite (HDM) sublingual immunotherapy (SLIT) for 48 weeks was effective as add-on treatment for allergic asthma; however, data regarding its long-term efficacy are scarce. Objective: We sought to evaluate the effect of HDM SLIT on asthma control, pulmonary function, and airway inflammation and remodeling throughout the 5-year treatment period. Methods: A total of 140 patients with asthma and allergic rhinitis sensitized to HDM were randomized to receive either drugs alone or drugs plus SLIT for 5 years. The 5-item Asthma Control Questionnaire (ACQ-5), Asthma Quality of Life Questionnaire (AQLQ), Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), spirometry, quantitative computed tomography, and type 2 biomarkers were assessed. Results: % predicted, airway wall area, Feno, and specific IgE was high. Multivariate regression analysis showed that the strongest predictor of responders was Feno. Conclusions: HDM SLIT continued to provide sustained efficacy, improve lung function, and prevent progression of airway inflammation and remodeling in asthma throughout the 5-year treatment period.

Topics & Concepts

MedicineExhaled nitric oxideAsthmaSlitHouse dust miteSpirometryEosinophilPulmonary function testingImmunologyArea under the curveInternal medicineImmunoglobulin EReceiver operating characteristicAllergyGastroenterologyAllergenAntibodyGeneticsBiologyAllergic Rhinitis and SensitizationAsthma and respiratory diseasesRespiratory and Cough-Related Research
Long-term efficacy of house dust mite sublingual immunotherapy on clinical and pulmonary function in patients with asthma and allergic rhinitis | Litcius